ArticleScientific reports2026
Ventilator-integrated humidified cold atmospheric plasma enables safe eradication of lung cancer cells and supports respiratory therapeutic applications.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Cold Atmospheric Plasma Against Methicillin-Resistant Staphylococcus aureus Biofilms: A Systematic Review of In Vitro Studies.BioMed research international · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold atmospheric plasma (CAP) generates reactive oxygen and nitrogen species (ROS/RNS) capable of selectively destroying pathogens and malignant cells while sparing normal tissue. The Canady Helios Cold Plasma (CHCP) HERO (Humidified Electrical Reactive Oxygen) System integrates a CAP generator with a ventilator platform to enable controlled, humidified plasma delivery through the respiratory tract. Efficacy and safety were assessed using A549 human lung carcinoma cells and an in vivo swine model. CAP was delivered with humidified Air/O₂ (1:1 v/v; 2 L·min⁻1) and helium (3 L·min⁻1) at 35–40 V, varying helium humidity (0–100%) and discharge mode (continuous or interval). Cell viability (MTT), ozone (O₃), and ROS/RNS (H₂O₂, NO₂⁻, NO₃⁻) were quantified, and physiological and histological assessments evaluated in vivo safety. A549 viability decreased significantly with increasing helium humidity [ANOVA, F(4, 10) = 1770.23, p = 3.3 × 10⁻14], with > 95% reduction within 5 min at 100% RH. Humidified Air/O₂ reduced O₃ output by 40–60% versus dry gas (p < 0.005). In swine model study, vital signs remained stable and lung histology showed intact alveoli without inflammation or edema; only TNF-α rose modestly (p < 0.05). The CHCP-HERO System achieved complete A549 eradication while maintaining physiological and histological safety, supporting CAP-based ventilation as a promising therapeutic gas system for respiratory infections and lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.